Neurofibromatosis 2: new perspectives in treatment (case report)
E. S. Makashova,
S. V. Zolotova,
V. V. Kostyuchenko,
M. V. Galkin,
M. A. Ginzberg,
G. V. Danilov,
N. A. Antipina,
N. A. Konovalov,
A. V. Golanov https://doi.org/10.17650/1683-3295-2021-23-1-109-118
Abstract
Neurofibromatosis 2 is one of the most prevalence disease among phakomatoses characterized by appearance of new central and peripheral nerve system tumors. The main treatment for this patient is a surgery, but in real time we observe the significant changes in treatment and rehabilitation in this patients including radiation therapy and pharmacotherapy. In this paper, we present the case of a different treatment options in young female with neurofibromatosis. She completed surgical treatment, Gamma Knife radiosurgery and bevacizumab on different stage of disease. Development of genetic and molecular methods and appearance of new way for treatment could help to achieve a good functional result and stable local control but new clinical and fundamental research are needed.
About the Authors
E. S. Makashova
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia; A.S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
86 Entuziastov Hwy, Moscow 111123, Russia
S. V. Zolotova
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
V. V. Kostyuchenko
Business Center of Neurosurgery
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
M. V. Galkin
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
M. A. Ginzberg
Research Center of Neurology
Russian Federation
Russian Federation
80 Volokolamskoe Hwy, Moscow 125367, Russia
G. V. Danilov
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
N. A. Antipina
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
N. A. Konovalov
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
A. V. Golanov
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
Russian Federation
Russian Federation
Andrey Vladimirovich Golanov
16 4 th Tverskaya-Yamskaya St., Moscow 125047, Russia
References
1. Blakeley J.O., Evans D.G., Adler J. et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2012;158A(1):24–41. DOI: 10.1002/ajmg.a.34359.
2. Evans D.G., Howard E., Giblin C. et al. Birth incidence and prevalence of tumor– prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010;152A(2):327–32. DOI: 10.1002/ajmg.a.33139.
3. Blakeley J. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. Curr Opin Otolaryngol Head Neck Surg 2012;20(5):372–9. DOI: 10.1097/MOO.0b013e328357d2ee.
4. Ruggieri M., Praticò A.D., Evans D.G. Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms. Semin Pediatr Neurol 2015;22(4):240–58. DOI: 10.1016/j.spen.2015.10.008.
5. Ammoun S., Hanemann C.O. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 2011;7(7):392–9. DOI: 10.1038/nrneurol.2011.82.
6. Huson S.M., Hughes R.A.C. The neurofibromatoses: a pathogenetic and clinical overview. London: Churchill Livingstone, 1994.
7. Wishart J.H. Case of tumours in the skull, dura mater, and brain. Edinb Med Surg J 1822;18(72):393–7.
8. Gardner W.J., Frazier C.H. Hereditary bilateral acoustic tumors. J Hered 1933;22:7–8.
9. Moyhuddin A., Baser M.E., Watson C. et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40(6):459–63. DOI: 10.1136/jmg.40.6.459.
10. Kluwe L., Mautner V., Heinrich B. et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109–14. DOI: 10.1136/jmg.40.2.109.
11. Baser M.E., Friedman J.M., Joe H. et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 2011;13(6):576–81. DOI: 10.1097/GIM.0b013e318211faa9.
12. Smith M.J., Bowers N.L., Bulman M. et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1- related schwannomatosis. Neurology 2017;88(1):87–92. DOI: 10.1212/WNL.0000000000003418.
13. Evans D.G., King A.T., Bowers N.L. et al. Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med 2019;21(7):1525–33. DOI: 10.1038/s41436-018-0384-y.
14. Baser M.E., Friedman J.M., Joe H. et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 2011;13(6):576–81. DOI: 10.1097/GIM.0b013e318211faa9.
15. Hanemann C.O., Blakeley J.O., Nunes F.P. et al. Current status and recommendations for biomarkers and biobanking in neurofbromatosis. Neurology 2016;87(7 Suppl 1):S40–8. DOI: 10.1212/WNL.0000000000002932.
16. Kuo H.C., Chen S.R., Jung S.M. et al. Neurofibromatosis 2 with peripheral neuropathies: electrophysiological, pathological and genetic studies of a Taiwanese family. Neuropathology 2010;30(5):515–23. DOI: 10.1111/j.1440-1789.2009.01099.x.
17. Sperfeld A.D., Hein C., Schröder J.M. et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002;125(Pt 5):996–1004. DOI: 10.1093/brain/awf115.
18. Pegat A., Ducray F., Jeannin-Mayer S. et al. Charcot–Marie–Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: a case report and review of the literature. Rev Neurol (Paris) 2019;175(7–8):486–9. DOI: 10.1016/j.neurol.2018.10.011.
19. Wentworth S., Pinn M., Bourland J.D. et al. Clinical experience with radiation therapy in the management of neurofibromatosis- associated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009;73(1):208–13. DOI: 10.1016/j.ijrobp.2008.03.073.
20. Slattery W.H., Lev M.H., Fisher L.M. et al. MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol 2005;26(4):733–40. DOI: 10.1097/01.mao.0000169048.15889.80.
21. Grey P.L., Moffat D.A., Palmer C.R. et al. Factors which influence the facial nerve outcome in vestibular schwannoma surgery. Clin Otolaryngol Allied Sci 1996;21(5):409–13. DOI: 10.1046/j.1365-2273.1996.00816.x.
22. Lustig L.R., Yeagle J., Driscoll C.L. et al. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol 2006;27(4):512–8. DOI: 10.1097/01.mao.0000217351.86925.51.
23. Trotter M.I., Briggs R.J. Cochlear implantation in neurofibromatosis type 2 after radiation therapy. Otol Neurotol 2010;31(2):216–9. DOI: 10.1097/MAO.0b013e3181c348e7.
24. Zhao Y., Liu P., Zhang N. et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 2018;115(9):E2077–84. DOI: 10.1073/pnas.1719966115.
25. Paldor I., Abbadi S., Bonne N. et al. The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. J Neurooncol 2017;135(1):47–56. DOI: 10.1007/s11060-017-2567-9.
26. Baser M.E., Evans D.G., Jackler R.K. et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000;82(4):998. DOI: 10.1054/bjoc.1999.1030.
27. Evans D.G., Birch J.M., Ramsden R.T. et al. Malignant transformation and new primary tumors after therapeutic radiation for benign disease: Substantial risks in certain tumor prone syndromes. J Med Genet 2006;43:289–94. DOI: 10.1136/jmg.2005.036319.
28. Mathieu D., Kondziolka D., Flickinger J.C. et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007;60(3):460–70. DOI: 10.1227/01.NEU.0000255340.26027.53.
29. Goutagny S., Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010;99(3):341–7. DOI: 10.1007/s11060-010-0339-x.
30. Mautner V.F., Lindenau M., Baser M.E. et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38(5):880–6. DOI: 10.1097/00006123-199605000-00004.
31. Dow G., Biggs N., Evans G. et al. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2005;2:574–9. DOI: 10.3171/spi.2005.2.5.0574.
32. Li W., Cooper J., Zhou L. et al. Merlin/ NF2 loss-driven tumorigenesis linked to CRL4 (DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 2014;26(1):48–60. DOI: 10.1016/j.ccr.2014.05.001.
33. Cayé-Thomasen P., Werther K., Nalla A. et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005;26:98–101. DOI: 10.1097/00129492-200501000-00017.
34. Ling B.C., Wu J., Miller S.J. et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005;7(1): 65–75. DOI: 10.1016/j.ccr.2004.10.016.
35. James M.F., Stivison E., Beauchamp R. et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 2012;10(5):649–59. DOI: 10.1158/1541-7786.MCR-11-0425-T.
36. Lim S.H., Ardern-Holmes S., McCowage G., de Souza P. Systemic therapy in neurofibromatosis type 2. Cancer Treat Rev 2014;40(7):857–61. DOI: 10.1016/j.ctrv.2014.05.004.
37. Plotkin S.R., Stemmer-Rachamimov A.O., Barker F.G. 2nd et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358–67. DOI: 10.1056/NEJMoa0902579.
38. Blakeley J.O., Ye X., Duda D.G. et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 2016;34(14):1669–75. DOI: 10.1200/JCO.2015.64.3817.
39. Lu V.M., Ravindran K., Graffeo C.S. et al. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and metaanalysis of treatment outcomes. J Neurooncol 2019;144(2):239–48. DOI: 10.1007/s11060-019-03234-8.
40. Goutagny S., Raymond E., Sterkers O. et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011;22(4):990–1. DOI: 10.1093/annonc/mdr012.
41. Goutagny S., Kalamarides M. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neurochirurgie 2018;64(5):370–4. DOI: 10.1016/j.neuchi.2016.09.004.
42. Nunes F.P., Merker V.L., Jennings D. et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013;8(3):e59941. DOI: 10.1371/journal.pone.0059941.
43. Alanin M.C., Klausen C., Caye- Thomasen P. et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series. Int J Neurosci 2016;126(11):1002–6. DOI: 10.3109/00207454.2015.1092443.
44. Morris K.A., Afridi S.K., Evans D. et al. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. J Neurosurg Spine 2017;26(4):474–82. DOI: 10.3171/2016.8.SPINE16589.
45. Morris K.A., Golding J.F., Axon P.R. et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract 2016;3(4):281–9. DOI: 10.1093/nop/npv065.
46. Osorio D.S., Hu J., Mitchell C. et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol 2018;139(3):749–55. DOI: 10.1007/s11060-018-2922-5.
47. Karajannis M.A., Legault G., Hagiwara M. et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012;14(9): 1163–70. DOI: 10.1093/neuonc/nos146.
48. Goutagny S., Giovannini M., Kalamarides M. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol 2017;133(2): 443–5. DOI: 10.1007/s11060-017-2447-3.
49. Ouerdani A., Goutagny S., Kalamarides M. et al. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2. Cancer Chemother Pharmacol 2016;77(6): 1263–73. DOI: 10.1007/s00280-016-3046-2.
Review
For citations:
Makashova E.S., Zolotova S.V., Kostyuchenko V.V., Galkin M.V., Ginzberg M.A., Danilov G.V., Antipina N.A., Konovalov N.A., Golanov A.V. Neurofibromatosis 2: new perspectives in treatment (case report). Russian journal of neurosurgery. 2021;23(1):109‑118. (In Russ.) https://doi.org/10.17650/1683-3295-2021-23-1-109-118
Views:
1075
Email this article 